345 related articles for article (PubMed ID: 31371432)
1. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
van Raalte DH; Bjornstad P; Persson F; Powell DR; de Cassia Castro R; Wang PS; Liu M; Heerspink HJL; Cherney D
Diabetes Care; 2019 Oct; 42(10):1921-1929. PubMed ID: 31371432
[TBL] [Abstract][Full Text] [Related]
2. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
[TBL] [Abstract][Full Text] [Related]
3. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
[TBL] [Abstract][Full Text] [Related]
4. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
[TBL] [Abstract][Full Text] [Related]
5. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
7. Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Stougaard EB; Rossing P; Vistisen D; Banks P; Girard M; Davies MJ; Persson F
Diabetes Obes Metab; 2023 Jul; 25(7):1874-1882. PubMed ID: 36872068
[TBL] [Abstract][Full Text] [Related]
8. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
[No Abstract] [Full Text] [Related]
9. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
10. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
Diabetologia; 2021 Jun; 64(6):1256-1267. PubMed ID: 33665685
[TBL] [Abstract][Full Text] [Related]
11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
12. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
Sridhar VS; Bhatt DL; Odutayo A; Szarek M; Davies MJ; Banks P; Pitt B; Steg PG; Cherney DZI
Clin J Am Soc Nephrol; 2024 May; 19(5):557-564. PubMed ID: 38277468
[TBL] [Abstract][Full Text] [Related]
13. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
[TBL] [Abstract][Full Text] [Related]
14. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Piperidou A; Sarafidis P; Boutou A; Thomopoulos C; Loutradis C; Alexandrou ME; Tsapas A; Karagiannis A
J Hypertens; 2019 Jul; 37(7):1334-1343. PubMed ID: 31145707
[TBL] [Abstract][Full Text] [Related]
15. Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.
Afkarian M; Polsky S; Parsa A; Aronson R; Caramori ML; Cherney DZ; Crandall JP; de Boer IH; Elliott TG; Galecki AT; Goldfine AB; Haw JS; Hirsch IB; Karger AB; Lingvay I; Maahs DM; McGill JB; Molitch ME; Perkins BA; Pop-Busui R; Pragnell M; Rosas SE; Rossing P; Senior P; Sigal RJ; Spino C; Tuttle KR; Umpierrez GE; Wallia A; Weinstock RS; Wu C; Mauer M; Doria A;
Diabetes Care; 2019 Aug; 42(8):1454-1463. PubMed ID: 31186299
[TBL] [Abstract][Full Text] [Related]
16. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
[TBL] [Abstract][Full Text] [Related]
17. Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy.
Hansen HP; Christensen PK; Tauber-Lassen E; Klausen A; Jensen BR; Parving HH
Kidney Int; 1999 Feb; 55(2):621-8. PubMed ID: 9987086
[TBL] [Abstract][Full Text] [Related]
18. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
J Diabetes Investig; 2021 Jan; 12(1):74-81. PubMed ID: 32506833
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Mosenzon O; Wiviott SD; Heerspink HJL; Dwyer JP; Cahn A; Goodrich EL; Rozenberg A; Schechter M; Yanuv I; Murphy SA; Zelniker TA; Gause-Nilsson IAM; Langkilde AM; Fredriksson M; Johansson PA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS; Raz I
Diabetes Care; 2021 Aug; 44(8):1805-1815. PubMed ID: 34233928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
